Prochymal III programs evaluated in Phase III programs for steroid-refractory graft-versus – host disease , acute GvHD and Crohn’s disease. Prochymal was fast track status from the U.S. FDA for GvHD and Crohn’s disease, and is the first stem cell product to receive FDA expanded access approval.

The %age the %age of blood pumped out a ventricle with each heart beat, is a common measure of the total heart function and typically declines after a heart attack. The target enrollment of 220 patients and to to Prochymal or placebo at 1:1. Efficacy endpoints of cardiac MRI are determined end-systolic volume, LVEF and the ability of Prochymal functional heart tissue and limit scar formation to keep after a heart attack. In addition, functional and quality-of-life assessments will be conducted.This application is based at clinical data that incorporate the results from the Company Stage 3 multi-center, international, randomized studies from Vidaza to treat patient with high-risk MDS. Patients at high risk 2007. Of Phase 3 the study was the superiority the overall survival for Vidaza opposite conventional treatment methods, and these data were American Society of Hematology American Society of Hematology in December 2007.

Pharmion CorporationPharmion Corporation announced high-risk MDS market for the inspection the company’s Marketing Authorization Application on Vidaza those patients with more be accepted risk myelodysplastic syndromes and announced that its intention to use application under Accelerated Assessment Procedure verify. Pharmion put to Vidaza MAA at the EMEA in this month.